Yow‐Ming Wang
Center for Biologics Evaluation and Research(US)United States Food and Drug Administration(US)Center for Drug Evaluation and Research(US)
Publications by Year
Research Areas
Biosimilars and Bioanalytical Methods, Pharmaceutical studies and practices, Monoclonal and Polyclonal Antibodies Research, Protein purification and stability, Statistical Methods in Clinical Trials
Most-Cited Works
- → c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo(2005)123 cited
- → Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective(2015)109 cited
- → Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin(2001)106 cited
- → Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies(2010)102 cited
- → 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)(2019)92 cited